LB Pharma's twist on old Sanofi drug passes schizophrenia test, teeing up phase 3 push

LB Pharmaceuticals has shared top-line data from a phase 2 schizophrenia trial, touting results that offer early support for its vision and putting it on track to start a pivotal study around the end of the year.